3-二甲氨基-1-(4-甲基苯基)-1-丙酮 | 13552-47-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-二甲氨基-1-(4-甲基苯基)-1-丙酮
• 英文名称: 3-(dimethylamino)-1-(p-tolyl)propan-1-one
• 英文别名: 3-dimethylamino-1-(4-methylphenyl)-1-propanone；3-(dimethylamino)-1-(4-methylphenyl)propan-1-one
• CAS: 13552-47-1
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: CDRIHKYUUKWROD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-二甲氨基-1-(4-甲基苯基)-1-丙酮 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以91%的产率得到3-二甲氨基-1-(4-甲基苯基)丙醇
  参考文献：
  名称：

  Design, parallel synthesis and SAR of novel urotensin II receptor agonists

  摘要：

  A 30-membered library of amides based on the potent urotensin II (UII) receptor agonist FL104, has been synthesized from ten different carboxylic acids and three amines. A synthetic protocol producing the amides in 47-98% yield has been developed in which the purification involved only extractions and in a few cases filtration through an ion-exchange resin. It was found that 5 mg of starting material was enough to obtain reproducible results and excellent purities. Thus, the procedure is estimated to be transferable to fully automated systems. The synthesized compounds were evaluated for their Ull receptor agonistic activities using a cell-based assay (R-SAT). The most active compounds were the 4-trifluoromethylcinnamic amides of 1-(4-chlorophenyt)-3-dimethylamino-propylamine and 1-(2-naphthyl)-3-dimethylamino-propylamine, both showed EC50 values of 130 nM. (c) 2006 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2006.09.015
• 作为产物：
  描述：

  1-(4-甲基苯基)-2-丙炔-1-醇 在 manganese(IV) oxide 、 频那醇硼烷 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 3-二甲氨基-1-(4-甲基苯基)-1-丙酮
  参考文献：
  名称：

  炔酮还原加氢胺化无金属合成β-氨基酮

  摘要：

  本研究描述了一种在非常温和的无金属条件下通过炔烃的还原加氢胺化合成 β-氨基酮的级联方法。它允许炔酮和胺快速转化为相应的β-氨基酮，具有广泛的底物范围和多种功能。这种简单易行的反应过程可成功应用于普罗克生和普罗哌卡因的合成，为合成具有β-氨基酮骨架的药物分子提供了潜在的选择。

  DOI：

  10.1039/d2cc00169a

文献信息

• GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS
  申请人：Samumed, LLC

  公开号：US20140243349A1

  公开（公告）日：2014-08-28

  The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

  本公开提供了激活Wnt/β-连环蛋白信号通路并因此治疗或预防与信号转导相关的疾病的γ-二酮或其类似物；这些疾病包括骨质疏松症和骨关节病；骨发育不全、骨缺陷、骨折、牙周病、耳硬化症、伤口愈合、颅颌面缺陷、溶骨性骨病、创伤性脑损伤或脊柱损伤、与中枢神经系统分化和发育相关的脑萎缩/神经系统疾病，包括帕金森病、中风、缺血性脑疾病、癫痫、阿尔茨海默病、抑郁症、躁郁症、精神分裂症；耳部疾病如耳蜗毛细胞丧失；眼部疾病如老年性黄斑变性、糖尿病性黄斑水肿或视网膜色素变性以及与干细胞分化和生长相关的疾病，如脱发、造血相关疾病和组织再生相关疾病。
• Alkylation of 4-Hydroxycoumarins by Ketone Mannich Bases. Synthesis of 4-Hydroxy-2-oxo-3-(3-oxoalkyl)-2<i>H</i>-1-benzopyrans
  作者：Pierfrancesco Bravo、Calimero Ticozzi、Giancarlo Cavicchio

  DOI：10.1055/s-1985-31376

  日期：——

  The reaction of 4-hydroxycoumarins with 2-dimethylaminoethyl ketones or with dimethylamine + vinyl ketones affords 4-hydroxy-2-oxo-3-(3-oxoalkyl)-2H-1-benzopyrans which undergo carbonyl olefination with methylenetriphenylphosphorane to give 3-(3-butenyl)-4-hydroxy-2-oxo-2H-1-benzopyrans [3-(3-butenyl)-4-hydroxycoumarins].

  4-羟基香豆素与2-二甲氨基乙基酮或二甲胺加乙烯基酮的反应产物是4-羟基-2-氧代-3-(3-氧代烷基)-2H-1-苯并吡喃。这些化合物可通过甲叉三苯基膦的羰基烯化反应转变为3-(3-丁烯基)-4-羟基-2-氧代-2H-1-苯并吡喃[3-(3-丁烯基)-4-羟基香豆素]。
• Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors
  作者：Yong-Yong Zheng、Zhi-Jie Weng、Peng Xie、Mei-Yu Zhu、Long-Xuan Xing、Jian-Qi Li

  DOI：10.1016/j.ejmech.2014.08.045

  日期：2014.10

  A series of aralkyl diamine derivatives were designed, synthesized, and evaluated for their triple reuptake inhibitory abilities. Compounds 18c (5-HT, NE, DA, IC50 = 389, 69, 238 nM), 36a (5-HT, NE, DA, IC50 = 378, 477, 247 nM), and 36d (5-HT, NE, DA, IC50 = 501, 206, 357 nM) showed in vivo activities in the rat forced swim test at 5, 10, and 20 mg/kg PO. 36a was identified as the most promising candidate

  设计，合成了一系列芳烷基二胺衍生物，并对其三重再摄取抑制能力进行了评估。化合物18c（5-HT，NE，DA，IC 50  = 389，69，238 nM），36a（5-HT，NE，DA，IC 50  = 378，477，247 nM）和36d（5-HT， NE，DA，IC 50  = 501、206、357 nM）在大鼠强迫游泳试验中以5、10和20 mg / kg PO表现出体内活性。36a被确定为本研究中最有前途的候选人。具体而言，36a对许多中枢神经系统相关靶标的单胺转运蛋白表现出高选择性。此外，36a 在临床前研究中显示出良好的药代动力学性质和可接受的安全性。
• Novel domino products from the reaction of phenyl vinyl ketone and its derivatives with cyclic ketones
  作者：H Surya Prakash Rao、K Jeyalakshmi、S.P Senthilkumar

  DOI：10.1016/s0040-4020(02)00091-1

  日期：2002.3

  Reaction of phenyl vinyl ketone with cyclopentanone under thermal conditions resulted in novel domino products, 1,5,9-triketones along with the expected 1,5-diketones. The 1,5,9-triketones were formed via a Michael–Michael-rearrangement pathway. On the other hand, reaction under basic conditions furnished a spiro[4.5]decanone, formed by domino pathways involving Michael–Michael-aldol condensation reactions

  苯基乙烯基酮与环戊酮在热条件下的反应产生了新的多米诺骨牌产品1,5,9-三酮以及预期的1,5-二酮。1,5,9-三酮是通过迈克尔-迈克尔重排途径形成的。另一方面，在基本条件下的反应提供了螺[4.5]癸酮，它是由涉及迈克尔-迈克尔-奥尔多缩合反应的多米诺途径形成的。微波介导的1,5,9-三酮的还原胺化-环化反应提供了全氢环戊四[ ij ]喹啉嗪衍生物。
• [EN] UROTENSIN II RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR DE L'UROTENSINE II
  申请人：ACADIA PHARM INC

  公开号：WO2003104216A1

  公开（公告）日：2003-12-18

  Disclosed are compounds of Formula I, or salts or prodrugs thereof, complexed with a human urotensin II receptor as defined herein. Also disclosed are compounds of Formula II, or salts or prodrugs thereof, as defined herein. Also disclosed are methods of modulating the activity of a urotensin II receptor using a compound of Formula I, or a compound of Formula II, or salts or prodrugs thereof. In addition, methods of treating diseases related to the activity of urotensin II receptors are disclosed.

  本文披露了根据本文所定义的与人类尿嘧啶 II 受体形成络合物的 Formula I 化合物，或其盐或前药。还披露了根据本文所定义的 Formula II 化合物，或其盐或前药。还披露了使用 Formula I 化合物、Formula II 化合物、或其盐或前药来调节尿嘧啶 II 受体活性的方法。此外，还披露了治疗与尿嘧啶 II 受体活性相关疾病的方法。